Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

No longer available × INDUSTRY × Urinary Bladder Neoplasms × Clear all

Status

Completed 156 Terminated 61 Recruiting 57 Active not recruiting 36 Unknown 26 Withdrawn 16 Not yet recruiting 9 Enrolling by invitation 3 Available 2 Suspended 1 No longer available 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 14 Multiple Myeloma 13 Recurrence 11 Neoplasms 10 Leukemia, Myeloid, Acute 9 Carcinoma, Non-Small-Cell Lung 9 Prostatic Neoplasms 6 Glioblastoma 6 Breast Neoplasms 6 Lymphoma 5 Lung Neoplasms 5 Pancreatic Neoplasms 4 Lymphoma, Non-Hodgkin 4 Colorectal Neoplasms 4 Carcinoma, Renal Cell 4 Triple Negative Breast Neoplasms 3 Sarcoma 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Glioma 3 Carcinoma 3 Small Cell Lung Carcinoma 2 Ovarian Neoplasms 2 Neoplasms by Site 2 Lymphoma, T-Cell, Cutaneous 2 Liver Neoplasms 2 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2 Leukemia 2 Hodgkin Disease 2 Gastrointestinal Stromal Tumors 2 Cholangiocarcinoma 2

Interventions

bemarituzumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03801278 2021-12-13

FPA144

Five Prime Therapeutics, Inc.

No longer available

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡